| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1008127780 |
| P356 | DOI | 10.1038/NRC903 |
| P698 | PubMed publication ID | 12360278 |
| P5875 | ResearchGate publication ID | 11097939 |
| P2093 | author name string | Theresa M Allen | |
| P2860 | cites work | Openings between defective endothelial cells explain tumor vessel leakiness | Q24681507 |
| Continuous cultures of fused cells secreting antibody of predefined specificity | Q26776979 | ||
| Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse | Q28204295 | ||
| Improving the efficacy of antibody-based cancer therapies | Q28208361 | ||
| Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies | Q30654864 | ||
| Tumor targeting using anti-her2 immunoliposomes. | Q30698442 | ||
| Differences in the intracellular fate of free and polymer-bound doxorubicin | Q30729281 | ||
| An address system in the vasculature of normal tissues and tumors | Q30874647 | ||
| Specialization of tumour vasculature | Q30896811 | ||
| Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis | Q31104590 | ||
| Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma | Q31819981 | ||
| Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma | Q32034092 | ||
| Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia | Q33338309 | ||
| Toxin-labeled monoclonal antibodies | Q33340345 | ||
| Radioimmunotherapy of small-volume disease of metastatic colorectal cancer | Q33341317 | ||
| Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs | Q33746856 | ||
| Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents | Q33914337 | ||
| Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma | Q33935031 | ||
| Pretargeting with the affinity enhancement system for radioimmunotherapy. | Q33941046 | ||
| Therapeutic radiopharmaceuticals | Q33973848 | ||
| In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors | Q34030193 | ||
| Liposome targeting to tumors using vitamin and growth factor receptors | Q34064184 | ||
| Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion | Q34111107 | ||
| Antibody therapy for residual disease in acute myelogenous leukemia | Q34187452 | ||
| The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy | Q34288933 | ||
| Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. | Q34386601 | ||
| Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials | Q34428750 | ||
| Radioimmunotherapy of B-cell non-Hodgkin's lymphoma | Q34433753 | ||
| Targeted drug conjugates: principles and progress | Q34455170 | ||
| Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates | Q34463640 | ||
| The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors | Q34463656 | ||
| Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments | Q34478304 | ||
| Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). | Q34528379 | ||
| Monoclonal antibody therapy for lymphoma: an update | Q34552428 | ||
| Radioimmunotherapy for acute leukemia | Q34608650 | ||
| Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia | Q34611183 | ||
| Designing immunotoxins for cancer therapy. | Q34630307 | ||
| Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome | Q36455711 | ||
| Increased liposome extravasation in selected tissues: effect of substance P. | Q37496547 | ||
| Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: a clinical phase I/II study | Q38283180 | ||
| Enhanced biorecognition and internalization of HPMA copolymers containing multiple or multivalent carbohydrate side-chains by human hepatocarcinoma cells | Q38294568 | ||
| Adventures in targeting | Q40603684 | ||
| Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies | Q40623388 | ||
| Bioactivities of ricin retained and its immunoreactivity to anti-ricin polyclonal antibodies alleviated through pegylation | Q40749798 | ||
| On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes | Q40775306 | ||
| Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo | Q40877722 | ||
| Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. | Q41262351 | ||
| Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. | Q42652797 | ||
| p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups | Q43564829 | ||
| Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells | Q43805954 | ||
| Design of novel bioconjugates for targeted drug delivery | Q43842901 | ||
| Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. | Q43875201 | ||
| Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids | Q43893541 | ||
| Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At | Q43989683 | ||
| Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma | Q44634049 | ||
| Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals | Q45714399 | ||
| Finite element model of antibody penetration in a prevascular tumor nodule embedded in normal tissue. | Q52057632 | ||
| Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. | Q53390272 | ||
| Effective targeted cytotoxicity of neuroblastoma cells. | Q54549517 | ||
| Cellular Trafficking and Cytotoxicity of Anti-Cd19-Targeted Liposomal Doxorubicin in B Lymphoma Cells | Q56141226 | ||
| Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures | Q71561921 | ||
| A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs | Q73203628 | ||
| Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin | Q73359089 | ||
| Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein | Q73504352 | ||
| Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy | Q73591264 | ||
| The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage | Q74008108 | ||
| In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach | Q74256478 | ||
| Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo | Q74342583 | ||
| Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer | Q74611832 | ||
| Antibody engineering | Q77148421 | ||
| Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma | Q77167898 | ||
| Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain Fvs | Q77357748 | ||
| Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin | Q77503026 | ||
| pH-sensitive, serum-stable and long-circulating liposomes as a new drug delivery system | Q77598631 | ||
| Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK) | Q77995333 | ||
| Correlations between the rate of intracellular release of endocytosed liposomal Doxorubicin and cytotoxicity as determined by a new assay | Q84073909 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 750-763 | |
| P577 | publication date | 2002-10-01 | |
| P1433 | published in | Nature Reviews Cancer | Q641657 |
| P1476 | title | Ligand-targeted therapeutics in anticancer therapy | |
| P478 | volume | 2 |
| Q36785184 | A Recombinant Secondary Antibody Mimic as a Target-specific Signal Amplifier and an Antibody Immobilizer in Immunoassays |
| Q28550592 | A Synthetic Aptamer-Drug Adduct for Targeted Liver Cancer Therapy |
| Q91886191 | A Warburg effect targeting vector designed to increase the uptake of compounds by cancer cells demonstrates glucose and hypoxia dependent uptake |
| Q44072303 | A call to ARMs: the promise of immunomodulatory small molecules |
| Q39026969 | A comprehensive map of molecular drug targets. |
| Q36110850 | A detachable coating of cholesterol-anchored PEG improves tumor targeting of cell-penetrating peptide-modified liposomes |
| Q38804836 | A leucine zipper pair-based lipid vesicle for image-guided therapy in breast cancer |
| Q33835328 | A modeling analysis of the effects of molecular size and binding affinity on tumor targeting |
| Q37258768 | A new concept for smart drug delivery: adhesion induced nanovector implosion |
| Q30461242 | A novel nested liposome drug delivery vehicle capable of ultrasound triggered release of its payload. |
| Q33501372 | A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapy |
| Q28474508 | A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer |
| Q51075189 | A novel therapeutic drug for colon cancer: EpCAM scFv-truncated protamine (tp)-siRNA. |
| Q38843320 | A peptide-based pH-sensitive drug delivery system for targeted ablation of cancer cells |
| Q33347563 | A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies |
| Q37974934 | A review of imaging methods for measuring drug release at nanometre scale: a case for drug delivery systems |
| Q51293476 | A smart multifunctional drug delivery nanoplatform for targeting cancer cells. |
| Q99562941 | AC Electrokinetics of Salt-Free Multilayered Polymer-Grafted Particles |
| Q39016466 | ATP-triggered anticancer drug delivery |
| Q49587716 | Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging |
| Q46880214 | Active tumor-targeted delivery of PEG-protein via transferrin-transferrin-receptor system |
| Q92326331 | Actively Targeted and Redox Responsive Delivery of Anticancer Drug by Chitosan Nanoparticles |
| Q36395999 | Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery |
| Q35898339 | Advancement and applications of peptide phage display technology in biomedical science |
| Q38827516 | Advances in Peptide Functionalization on Mesoporous Silica Nanoparticles for Controlled Drug Release |
| Q38406190 | Advances in lipid-based drug delivery: enhancing efficiency for hydrophobic drugs |
| Q38316388 | Advances in the synthesis and application of nanoparticles for drug delivery |
| Q38741706 | An Enzyme-Directed Imidazoquinoline for Cancer Immunotherapy. |
| Q37090589 | An anti-PSMA bivalent immunotoxin exhibits specificity and efficacy for prostate cancer imaging and therapy |
| Q30381757 | An antibody-recruiting small molecule that targets HIV gp120. |
| Q38865143 | An enhanced ascorbate peroxidase 2/antibody-binding domain fusion protein (APEX2-ABD) as a recombinant target-specific signal amplifier |
| Q33529309 | An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo |
| Q33679533 | An integrated approach for the rational design of nanovectors for biomedical imaging and therapy |
| Q38840381 | An unusual role of folate in the self-assembly of heparin-folate conjugates into nanoparticles |
| Q39001270 | Anti-neuropilin 1 antibody Fab' fragment conjugated liposomal docetaxel for active targeting of tumours |
| Q33645821 | Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer |
| Q36438481 | Antibodies for targeted cancer therapy -- technical aspects and clinical perspectives |
| Q36373103 | Antibody targeted drugs as cancer therapeutics |
| Q36108119 | Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease |
| Q37076367 | Antibody-targeted liposomes in cancer therapy and imaging |
| Q37738158 | Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma |
| Q53625899 | Antitumor drug delivery modulated by a polymeric micelle with an upper critical solution temperature. |
| Q41115572 | Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration |
| Q33947942 | Apoptotic mechanism of human leukemia K562/A02 cells induced by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin |
| Q36161132 | Application of poly(ethylene glycol)-distearoylphosphatidylethanolamine (PEG-DSPE) block copolymers and their derivatives as nanomaterials in drug delivery |
| Q35754246 | Aspartate-modified doxorubicin on its N-terminal increases drug accumulation in LAT1-overexpressing tumors |
| Q35636332 | Assessing the transport of receptor-mediated drug-delivery devices across cellular monolayers |
| Q49769214 | Assessment of lactoferrin-conjugated solid lipid nanoparticles for efficient targeting to the lung |
| Q37700995 | Automated modular synthesis of aptamer-drug conjugates for targeted drug delivery. |
| Q42153678 | Bile Acid Conjugated DNA Chimera that Conditionally Inhibits Carbonic Anhydrase-II in the Presence of MicroRNA-21. |
| Q36160333 | Biological rationale for the design of polymeric anti-cancer nanomedicines |
| Q39829640 | Biomedical Nanomagnetics: A Spin Through Possibilities in Imaging, Diagnostics, and Therapy |
| Q55209384 | Biomimetic strategies for targeted nanoparticle delivery. |
| Q36635472 | Bioorthogonal Catalysis: A General Method To Evaluate Metal-Catalyzed Reactions in Real Time in Living Systems Using a Cellular Luciferase Reporter System |
| Q37218120 | Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells |
| Q57373258 | Biosynthetic-Synthetic Polymer Conjugates |
| Q88542591 | Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors |
| Q27330200 | CXCR-4 Targeted, Short Wave Infrared (SWIR) Emitting Nanoprobes for Enhanced Deep Tissue Imaging and Micrometastatic Cancer Lesion Detection |
| Q33539508 | Cancer cell-specific internalizing ligands from phage displayed beta-lactamase-peptide fusion libraries |
| Q40725853 | Cancer immunotherapy turns viral |
| Q37955451 | Cancer nanomedicines targeting tumor extracellular pH. |
| Q27021820 | Cancer nanotechnology: emerging role of gold nanoconjugates |
| Q29615481 | Cancer nanotechnology: opportunities and challenges |
| Q34447986 | Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. |
| Q36515785 | Cancer treatment using peptides: current therapies and future prospects |
| Q60955779 | Cell penetrating peptides in preclinical and clinical cancer diagnosis and therapy |
| Q33834772 | Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy |
| Q36417295 | Challenges and opportunities in the advancement of nanomedicines |
| Q36346851 | Challenges in design and characterization of ligand-targeted drug delivery systems |
| Q37992525 | Challenges in development of nanoparticle-based therapeutics |
| Q38162098 | Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology |
| Q38752059 | Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes |
| Q37478039 | Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer |
| Q38928032 | Chemically synthesized molecules with the targeting and effector functions of antibodies. |
| Q57368199 | Chitosan oligosaccharide copolymer micelles with double disulphide linkage in the backbone associated by H-bonding duplexes for targeted intracellular drug delivery |
| Q65556503 | Clinical cancer nanomedicine |
| Q90169830 | Co-delivery of glycyrrhizin and doxorubicin by alginate nanogel particles attenuates the activation of macrophage and enhances the therapeutic efficacy for hepatocellular carcinoma |
| Q38709499 | Co-delivery of insulin-like growth factor 1 receptor specific siRNA and doxorubicin using chitosan-based nanoparticles enhanced anticancer efficacy in A549 lung cancer cell line |
| Q55686642 | Colloidal Polymeric Platform for Facile Click-Assisted Ligand Functionalization and Receptor Targeting. |
| Q26747546 | Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET |
| Q37107517 | Combination chemotherapy and photodynamic therapy with fab' fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells |
| Q90233040 | Comparison between Fractionated Dose and Single Dose of Cu-64 Trastuzumab Therapy in the NCI-N87 Gastric Cancer Mouse Model |
| Q39098106 | Complexation of cell-penetrating peptide-polymer conjugates with polyanions controls cells uptake of HPMA copolymers and anti-tumor activity |
| Q35545342 | Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. |
| Q38783865 | Construction and characterization of gelonin and saporin plasmids for toxic gene-based cancer therapy |
| Q48935828 | Coupling of Ligands to the Liposome Surface by Click Chemistry |
| Q37076372 | Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug. |
| Q37697419 | Cross-linkable liposomes stabilize a magnetic resonance contrast-enhancing polymeric fastener |
| Q90662894 | Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide |
| Q36316931 | Current advances in sustained-release systems for parenteral drug delivery |
| Q38126543 | Current trends in the use of liposomes for tumor targeting |
| Q38362427 | Current understanding of synergistic interplay of chitosan nanoparticles and anticancer drugs: merits and challenges |
| Q30390185 | Cytochrome C encapsulating theranostic nanoparticles: a novel bifunctional system for targeted delivery of therapeutic membrane-impermeable proteins to tumors and imaging of cancer therapy |
| Q38730357 | DNA Interstrand Crosslinks by H-pin Polyamide (S)-seco-CBI Conjugates |
| Q28485909 | DOTA-functionalized polylysine: a high number of DOTA chelates positively influences the biodistribution of enzymatic conjugated anti-tumor antibody chCE7agl |
| Q50099552 | Dehydroascorbic Acid and pGPMA Dual Modified pH-Sensitive Polymeric Micelles for Target Treatment of Liver Cancer |
| Q33681427 | Dehydroascorbic Acids-modified Polymer Micelles Target Cancer Cells to Enhance Anti-tumor Efficacy of Paclitaxel |
| Q38122177 | Delivering flavonoids into solid tumors using nanotechnologies |
| Q30446963 | Delivery of cancer therapeutics using nanotechnology |
| Q42553783 | Design of smart HPMA copolymer-based nanomedicines |
| Q38067265 | Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. |
| Q34952473 | Design, synthesis, and biological functionality of a dendrimer-based modular drug delivery platform |
| Q36307576 | Designing polymers with sugar-based advantages for bioactive delivery applications |
| Q64899019 | Detachment of ligands from nanoparticle surface under flow and endothelial cell contact: Assessment using microfluidic devices. |
| Q41653596 | Development and Application of a Novel Model System to Study "Active" and "Passive" Tumor Targeting |
| Q36072878 | DiR-labeled Embryonic Stem Cells for Targeted Imaging of in vivo Gastric Cancer Cells |
| Q38862473 | Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL? |
| Q40005854 | Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles |
| Q37764989 | Drug delivery to solid tumors by elastin-like polypeptides |
| Q33800277 | Dual-targeted peptide-conjugated multifunctional fluorescent probe with AIEgen for efficient nucleus-specific imaging and long-term tracing of cancer cells |
| Q38792917 | EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model |
| Q27012856 | Echographic imaging of tumoral cells through novel nanosystems for image diagnosis. |
| Q42170543 | Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems |
| Q42373834 | Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors |
| Q38761421 | Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line. |
| Q39378811 | Efficient intracellular delivery of camptothecin by silica/titania hollow nanoparticles |
| Q38263314 | Elastin-like polypeptide for improved drug delivery for anticancer therapy: preclinical studies and future applications |
| Q35560114 | Endosomal pH-Responsive Polymer-Based Dual-Ligand-Modified Micellar Nanoparticles for Tumor Targeted Delivery and Facilitated Intracellular Release of Paclitaxel |
| Q33224253 | Engineering lipid vesicles of enhanced intratumoral transport capabilities: correlating liposome characteristics with penetration into human prostate tumor spheroids. |
| Q45301471 | Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies |
| Q35162175 | Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with Luteinizing Hormone-Releasing Hormone (LHRH) peptide. |
| Q36248528 | Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor |
| Q61135293 | Enhanced immunocompatibility of ligand-targeted liposomes by attenuating natural IgM absorption |
| Q35087556 | Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides |
| Q38886370 | Enhanced small interfering RNA delivery into cells by exploiting the additive effect between photo-sensitive peptides and targeting ligands |
| Q42380337 | Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors |
| Q39650842 | Enriching lipid nanovesicles with short‐chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors |
| Q98771513 | Enzyme-Responsive Nanoparticles for Anti-tumor Drug Delivery |
| Q26992127 | Enzyme-responsive nanomaterials for controlled drug delivery |
| Q38218799 | Erythrocytes-based synthetic delivery systems: transition from conventional to novel engineering strategies |
| Q34905683 | Evaluation of nanoparticle uptake in co-culture cancer models |
| Q34079536 | Facile method for the site-specific, covalent attachment of full-length IgG onto nanoparticles |
| Q34287997 | Factor VII light chain-targeted lidamycin shows intensified therapeutic efficacy for liver cancer |
| Q48093474 | Fast functionalization of ultrasound microbubbles using strain promoted click chemistry. |
| Q47313606 | Fate of Multimeric Oligomers, Submicron, and Micron Size Aggregates of Monoclonal Antibodies Upon Subcutaneous Injection in Mice |
| Q46277986 | Fluorogenic reaction-based prodrug conjugates as targeted cancer theranostics |
| Q92368275 | Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems |
| Q30464743 | Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound |
| Q55652135 | Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies. |
| Q48093281 | Frizzled7 Antibody-Functionalized Nanoshells Enable Multivalent Binding for Wnt Signaling Inhibition in Triple Negative Breast Cancer Cells. |
| Q57344870 | Functional aqueous assemblies of linear-dendron hybrids |
| Q48243945 | Functionalized Nanoparticles Efficiently Enhancing the Targeted Delivery, Tumor Penetration, and Anticancer Activity of 7-Ethyl-10-Hydroxycamptothecin. |
| Q57341247 | Functionally Engineered Sol-Gel Derived Inorganic Gels and Hybrid Nanoarchitectures for Biomedical Applications |
| Q46410888 | Furan-functionalized co-polymers for targeted drug delivery: characterization, self-assembly and drug encapsulation |
| Q47813155 | Fusion of gelonin and anti-insulin-like growth factor-1 receptor (IGF-1R) affibody for enhanced brain cancer therapy |
| Q33934981 | G protein-coupled receptors function as logic gates for nanoparticle binding and cell uptake. |
| Q34057731 | Genome-free viral capsids as multivalent carriers for taxol delivery |
| Q98181251 | Glycoconjugated metal complexes as cancer diagnostic and therapeutic agents |
| Q83528769 | Glycyrrhetinic acid-functionalized degradable micelles as liver-targeted drug carrier |
| Q38189490 | Guiding principles in the design of ligand-targeted nanomedicines. |
| Q42782242 | HPMA-based polymer therapeutics improve the efficacy of surgery, of radiotherapy and of chemotherapy combinations |
| Q64921561 | Hyaluronic Acid Layered Chimeric Nanoparticles: Targeting MAPK-PI3K Signaling Hub in Colon Cancer Cells. |
| Q52593653 | Hybrid Drug Delivery Patches Based on Spherical Cellulose Nanocrystals and Colloid Titania-Synthesis and Antibacterial Properties. |
| Q38431574 | Hybrid nanoparticles for cancer imaging and therapy |
| Q38675885 | Hybridization chain reaction: a versatile molecular tool for biosensing, bioimaging, and biomedicine |
| Q57610433 | Hydration forces as a tool for the optimization of core–shell nanoparticle vectors for cancer gene therapy |
| Q92343797 | Hydrophilic Small Molecules That Harness Transthyretin To Enhance the Safety and Efficacy of Targeted Chemotherapeutic Agents |
| Q37617137 | Imaging in targeted delivery of therapy to cancer |
| Q38042256 | Immunoconjugates and long circulating systems: origins, current state of the art and future directions |
| Q90288702 | Impact of conjugation strategies for targeting of antibodies in gold nanoparticles for ultrasensitive detection of 17β-estradiol |
| Q39114835 | Improved Targeting of Cancers with Nanotherapeutics |
| Q42910320 | In Silico Design and Analysis of TGFαL3-SEB Fusion Protein as "a New Antitumor Agent" Candidate by Ligand-Targeted Superantigens Technique |
| Q38253121 | In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin B-cell lymphoma |
| Q39385032 | In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin |
| Q38936986 | In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells |
| Q37202303 | In vivo Biocompatibility, Biodistribution and Therapeutic Efficiency of Titania Coated Upconversion Nanoparticles for Photodynamic Therapy of Solid Oral Cancers. |
| Q39590398 | In vivo targeting of alveolar macrophages via RAFT-based glycopolymers |
| Q37404658 | Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics. |
| Q35912798 | Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release |
| Q89966843 | Interactions at the cell membrane and pathways of internalization of nano-sized materials for nanomedicine |
| Q28391849 | Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine |
| Q35566694 | Internalization: acute apoptosis of breast cancer cells using herceptin-immobilized gold nanoparticles |
| Q35946287 | Intrabodies: production and promise |
| Q36220307 | Intracellular GSH-activated galactoside photosensitizers for targeted photodynamic therapy and chemotherapy. |
| Q35226332 | Intracellular antibodies and challenges facing their use as therapeutic agents |
| Q36558003 | Intracellular calcium is a target of modulation of apoptosis in MCF-7 cells in the presence of IgA adsorbed to polyethylene glycol. |
| Q38718630 | Investigation of the mutagenic and genotoxic activities of LLL-3, a STAT3 inhibitor. |
| Q38999820 | Lactobionic acid coupled liposomes: an innovative strategy for targeting hepatocellular carcinoma. |
| Q34227310 | Landscape phages and their fusion proteins targeted to breast cancer cells |
| Q101137932 | Leukocyte-mimetic liposomes penetrate into tumor spheroids and suppress spheroid growth by encapsulated doxorubicin |
| Q41897403 | Ligand-decorated nanogels: fast one-pot synthesis and cellular targeting |
| Q35157616 | Ligand-targeted liposomal anticancer drugs |
| Q39632233 | Light induced drug delivery into cancer cells |
| Q38624989 | Light-Controlled Cellular Internalization and Cytotoxicity of Nucleic Acid-Binding Agents: Studies in Vitro and in Zebrafish Embryos |
| Q34199790 | Light-Induced Content Release from Plasmon Resonant Liposomes |
| Q33911056 | Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic |
| Q37679954 | Liposomal cancer therapy: exploiting tumor characteristics |
| Q38806793 | Liposomal drug delivery systems for targeted cancer therapy: is active targeting the best choice? |
| Q43242497 | Liposome-mediated therapy of neuroblastoma |
| Q64119596 | Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response |
| Q34079574 | Macromolecular therapeutics |
| Q35553201 | Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting |
| Q92922338 | Measurement of Tumor Pressure and Strategies of Imaging Tumor Pressure for Radioimmunotherapy |
| Q49987131 | Mechanistic Investigation and Multiplexing of Liposome-Assisted Metabolic Glycan Labeling |
| Q37806969 | Medical applications of organic–inorganic hybrid materials within the field of silica-based bioceramics |
| Q58022660 | Micellar drug nanocarriers and biomembranes: how do they interact? |
| Q37032639 | MicroRNAs as targets for antisense-based therapeutics |
| Q30454718 | Microbubble-mediated ultrasound therapy: a review of its potential in cancer treatment |
| Q52397658 | Microfluidic co-culture devices to assess penetration of nanoparticles into cancer cell mass. |
| Q30418235 | Microparticle adhesive dynamics and rolling mediated by selectin-specific antibodies under flow |
| Q38852205 | Molecular Assembly of Polysaccharide-Based Microcapsules and Their Biomedical Applications |
| Q28484348 | Molecular evolution of peptide ligands with custom-tailored characteristics for targeting of glycostructures |
| Q50724224 | Molecular tumor targeting of gelonin by fusion with F3 peptide. |
| Q27343143 | Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel |
| Q38856643 | Multifunctional Nanoparticles Self-Assembled from Small Organic Building Blocks for Biomedicine |
| Q39180827 | Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral chemotherapy. |
| Q37967150 | Multifunctional dendritic polymers in nanomedicine: opportunities and challenges. |
| Q39017324 | Multifunctional nanoassemblies of block copolymers for future cancer therapy |
| Q38119471 | Multifunctional nanomicellar systems for delivering anticancer drugs. |
| Q37564506 | Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy |
| Q27011598 | Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities |
| Q36969145 | Multifunctional nanoparticulate polyelectrolyte complexes |
| Q37222159 | Multimodality nanotracers for cardiovascular applications. |
| Q89127555 | NFATC3-PLA2G15 Fusion Transcript Identified by RNA Sequencing Promotes Tumor Invasion and Proliferation in Colorectal Cancer Cell Lines |
| Q38128317 | Nanocarrier-mediated targeting of tumor and tumor vascular cells improves uptake and penetration of drugs into neuroblastoma. |
| Q26740048 | Nanocarriers Usage for Drug Delivery in Cancer Therapy |
| Q29616699 | Nanocarriers as an emerging platform for cancer therapy |
| Q38523681 | Nanocarriers for cancer-targeted drug delivery. |
| Q38634048 | Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation |
| Q35019550 | Nanomedical engineering: shaping future nanomedicines |
| Q34247073 | Nanomedicine--challenge and perspectives |
| Q36597647 | Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs |
| Q38247299 | Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. |
| Q29615628 | Nanoparticle therapeutics: an emerging treatment modality for cancer |
| Q33793300 | Nanoparticles containing octreotide peptides and gadolinium complexes for MRI applications. |
| Q37330824 | Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel |
| Q38250517 | Nanoparticulate carriers: an emerging tool for breast cancer therapy |
| Q36807625 | Nanostructured materials for applications in drug delivery and tissue engineering |
| Q36597461 | Nanostructured porous Si-based nanoparticles for targeted drug delivery |
| Q30452478 | Nanotechnology and cancer |
| Q36842770 | Nanotechnology for targeted cancer therapy |
| Q59049899 | Nanotechnology in Cancer Drug Delivery and Selective Targeting |
| Q34112647 | Nanotechnology in drug delivery and tissue engineering: from discovery to applications |
| Q37785935 | Nanotheranostics and Image-Guided Drug Delivery: Current Concepts and Future Directions |
| Q37058812 | Nanovehicular intracellular delivery systems |
| Q37669341 | Naptumomab estafenatox: a new immunoconjugate |
| Q40382220 | Near-Infrared Fluorescent Ag2 Se-Cetuximab Nanoprobes for Targeted Imaging and Therapy of Cancer |
| Q37032641 | Neutrophils in antibody-based immunotherapy of cancer |
| Q41033340 | Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities |
| Q35087229 | Novel HPMA copolymer-bound constructs for combined tumor and mitochondrial targeting |
| Q33502835 | Novel beta-lactamase-random peptide fusion libraries for phage display selection of cancer cell-targeting agents suitable for enzyme prodrug therapy |
| Q34698624 | Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine |
| Q36459196 | Odyssey of a cancer nanoparticle: from injection site to site of action |
| Q35256650 | On the mechanism of targeting of phage fusion protein-modified nanocarriers: only the binding peptide sequence matters |
| Q36723089 | On-Demand Targeting: Investigating Biology with Proximity-Directed Chemistry |
| Q42546451 | Optimization of photoactive protein Z for fast and efficient site-specific conjugation of native IgG. |
| Q60240408 | Organoruthenium and Osmium Anticancer Complexes Bearing a Maleimide Functional Group: Reactivity to Cysteine, Stability, and Cytotoxicity |
| Q37657516 | Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction |
| Q42817052 | P53-Derived peptides conjugation to PEI: an approach to producing versatile and highly efficient targeted gene delivery carriers into cancer cells. |
| Q92403213 | PEG-Derivatized Dual-Functional Nanomicelles for Improved Cancer Therapy |
| Q36777280 | PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting |
| Q38167826 | PEGylated nanomedicines: recent progress and remaining concerns |
| Q36376467 | POLYMERIC BIOMATERIALS AND NANOMEDICINES. |
| Q38938291 | PSMA-mediated endosome escape-accelerating polymeric micelles for targeted therapy of prostate cancer and the real time tracing of their intracellular trafficking |
| Q33592506 | Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity |
| Q47794249 | Particle Targeting in Complex Biological Media |
| Q38214156 | Penetrating the cell membrane, thermal targeting and novel anticancer drugs: the development of thermally targeted, elastin-like polypeptide cancer therapeutics |
| Q42641268 | Peptide-containing aggregates as selective nanocarriers for therapeutics. |
| Q39445066 | Peptide-directed HPMA copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer |
| Q39691146 | Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells. |
| Q28538039 | Peptide-mediated liposomal Doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models |
| Q33829569 | Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy |
| Q36119579 | Peptide-mediated targeting of liposomes to TrkB receptor-expressing cells |
| Q35783096 | Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates |
| Q47661007 | Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. |
| Q24645548 | Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer |
| Q61798043 | Photo-Cured Glycol Chitosan Hydrogel for Ovarian Cancer Drug Delivery |
| Q48642623 | Photochemical internalization in bladder cancer - development of an orthotopic in vivo model |
| Q50865525 | Plant Toxin-Based Immunotoxins for Cancer Therapy: A Short Overview. |
| Q52584448 | Poly(Ethylene Glycol)-Polylactide Micelles for Cancer Therapy. |
| Q36561667 | Polymer conjugates as anticancer nanomedicines |
| Q37782076 | Polymer-drug conjugates for novel molecular targets |
| Q90694715 | Polymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy |
| Q30372383 | Polymeric Nanostructures for Imaging and Therapy |
| Q50960383 | Polymeric micelles for targeted tumor therapy of platinum anticancer drugs. |
| Q50169459 | Polymeric microneedles for transdermal protein delivery |
| Q39117499 | Polyphenols delivery by polymeric materials: challenges in cancer treatment. |
| Q37510967 | Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer |
| Q45943066 | Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumours. |
| Q59128137 | Preparation and Characterization of Inulin Coated Gold Nanoparticles for Selective Delivery of Doxorubicin to Breast Cancer Cells |
| Q38901380 | Preparation and In Vitro Evaluation of Antitumor Activity of TGFαL3-SEB as a Ligand-Targeted Superantigen. |
| Q41917876 | Preparation and Practical Applications of 2',7'-Dichlorodihydrofluorescein in Redox Assays |
| Q33560821 | Preparation and evaluation of norcantharidin-encapsulated liposomes modified with a novel CD19 monoclonal antibody 2E8. |
| Q31163344 | Preparation and functional studies of hydroxyethyl chitosan nanoparticles loaded with anti-human death receptor 5 single-chain antibody |
| Q35074804 | Prevention of peritoneal adhesions using polymeric rheological blends |
| Q38362491 | Principles in the design of ligand-targeted cancer therapeutics and imaging agents. |
| Q60938672 | Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases |
| Q59229081 | Pros and cons of bifunctional platinum(iv) antitumor prodrugs: two are (not always) better than one |
| Q45018017 | Protein functionalized tramadol-loaded PLGA nanoparticles: preparation, optimization, stability and pharmacodynamic studies |
| Q84078785 | Protein-protein docking on molecular models of Aspergillus niger RNase and human actin: novel target for anticancer therapeutics |
| Q42269128 | Pulmonary delivery of triptolide-loaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy |
| Q30426788 | Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors |
| Q51307074 | Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. |
| Q37237705 | Radionuclide carriers for targeting of cancer |
| Q40080152 | Radiotherapy augments the immune response to prostate cancer in a time-dependent manner |
| Q35606767 | Rational design and engineering of delivery systems for therapeutics: biomedical exercises in colloid and surface science. |
| Q41137859 | Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor |
| Q26747764 | Recent advancements in erythrocytes, platelets, and albumin as delivery systems |
| Q35845362 | Recent advances in targeted endoscopic imaging: Early detection of gastrointestinal neoplasms |
| Q37603355 | Recent advances in tumor vasculature targeting using liposomal drug delivery systems. |
| Q33573762 | Recent trends in targeted anticancer prodrug and conjugate design |
| Q37804383 | Receptor-targeted nanocarriers for therapeutic delivery to cancer |
| Q38053177 | Red blood cells and polyelectrolyte multilayer capsules: natural carriers versus polymer-based drug delivery vehicles |
| Q50178573 | Role of 6-Mercaptopurine in the potential therapeutic targets DNA base pairs and G-quadruplex DNA: insights from quantum chemical and molecular dynamics simulations |
| Q37957858 | Role of antibodies in cancer targeting |
| Q35652998 | Selective Tumor Targeting of Desacetyl Vinblastine Hydrazide and Tubulysin B via Conjugation to a Cholecystokinin 2 Receptor (CCK2R) Ligand |
| Q33230098 | Selective delivery of therapeutic agents for the diagnosis and treatment of cancer |
| Q40494672 | Selective induction of apoptosis in MCF7 cancer-cell by targeted liposomes functionalised with mannose-6-phosphate. |
| Q38599130 | Self-Assembled Smart Nanocarriers for Targeted Drug Delivery |
| Q64975341 | Self-Triggered Apoptosis Enzyme Prodrug Therapy (STAEPT): Enhancing Targeted Therapies via Recurrent Bystander Killing Effect by Exploiting Caspase-Cleavable Linker. |
| Q39290416 | Self-assembling nanoparticles for the release of bisphosphonates in the treatment of human cancers [WO2012042024]. |
| Q37464325 | Self-assembling peptide amphiphile-based nanofiber gel for bioresponsive cisplatin delivery |
| Q39134842 | Self-assembly of renewable nano-sized triterpenoids |
| Q37045947 | Serum Stability and Affinity Optimization of an M2 Macrophage-Targeting Peptide (M2pep). |
| Q79086581 | Silent, but deadly – eliminating reservoirs of latent HIV |
| Q33385557 | Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery |
| Q56483139 | Small particles, big impacts: A review of the diverse applications of nanofluids |
| Q38626956 | Smart Nanoscale Drug Delivery Platforms from Stimuli-Responsive Polymers and Liposomes. |
| Q38960517 | Spatiotemporally programmable surface engineered nanoparticles for effective anticancer drug delivery |
| Q33767470 | Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv |
| Q40108216 | Specific targeting to murine myeloma cells of Cyt1Aa toxin from Bacillus thuringiensis subspecies israelensis |
| Q37132800 | State of the art in tumor antigen and biomarker discovery. |
| Q39167606 | Statins anticancer targeted delivery systems: re-purposing an old molecule. |
| Q47145115 | Stimuli-responsive nanocarriers for intracellular delivery |
| Q38968910 | Strategies for improving drug delivery: nanocarriers and microenvironmental priming |
| Q34094167 | Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma |
| Q49424319 | Supramolecular aptamer nano-constructs for receptor-mediated targeting and light-triggered release of chemotherapeutics into cancer cells. |
| Q50094691 | Supramolecular assembly of fluorogenic glyco-dots from perylenediimide-based glycoclusters for targeted imaging of cancer cells |
| Q38899902 | Surface functionalization of polymeric nanoparticles for tumor drug delivery: approaches and challenges. |
| Q36988355 | Surface-active liposomes for targeted cancer therapy |
| Q50523900 | Surface-modified loaded human red blood cells for targeting and delivery of drugs. |
| Q34701443 | Synthesis and antitumor efficacy of daunorubicin-loaded magnetic nanoparticles |
| Q41553128 | Synthesis and characterization of a new class of cationic protein polymers for multivalent display and biomaterial applications |
| Q35104686 | Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20. |
| Q38721673 | Synthesis and evaluation of pH-sensitive, self-assembled chitosan-based nanoparticles as efficient doxorubicin carriers |
| Q33762115 | Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome |
| Q36320557 | Synthesis of novel cyclic NGR/RGD peptide analogs via on resin click chemistry |
| Q31037467 | Synthesis of some new porphyrins and their metalloderivatives as potential sensitizers in photo-dynamic therapy |
| Q47589446 | Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications |
| Q34684423 | Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting |
| Q41129373 | Tagging staphylococcal enterotoxin B (SEB) with TGFaL3 for breast cancer therapy |
| Q48230981 | Targeted Photodynamic Therapy with a Folate/Sensitizer Assembly Produced from Mesoporous Silica. |
| Q49787181 | Targeted Therapeutic Nanoparticles: An Immense Promise to Fight against Cancer. |
| Q41346523 | Targeted and ultrasound-triggered cancer cell injury using perfluorocarbon emulsion-loaded liposomes endowed with cancer cell-targeting and fusogenic capabilities. |
| Q38309779 | Targeted and ultrasound-triggered drug delivery using liposomes co-modified with cancer cell-targeting aptamers and a thermosensitive polymer. |
| Q35641242 | Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins |
| Q28485859 | Targeted delivery of immunotoxin by antibody to ganglioside GD3: a novel drug delivery route for tumor cells |
| Q35915020 | Targeted delivery of nanomedicines |
| Q37129235 | Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells |
| Q35031676 | Targeted images of KB cells using folate-conjugated gold nanoparticles |
| Q38179032 | Targeted liposomal drug delivery systems for the treatment of B cell malignancies |
| Q36799773 | Targeted nanoparticle-based drug delivery and diagnosis |
| Q36934007 | Targeted polymeric therapeutic nanoparticles: design, development and clinical translation |
| Q27023361 | Targeted therapy using nanotechnology: focus on cancer |
| Q38169752 | Targeted thermosensitive liposomes: an attractive novel approach for increased drug delivery to solid tumors |
| Q33465023 | Targeting and internalization of sterically stabilized liposome modified with ZCH-4-2E8. |
| Q35972322 | Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody. |
| Q36078281 | Targeting of BRAF resistant melanoma via extracellular matrix metalloproteinase inducer receptor |
| Q39092356 | Targeting of herbal bioactives through folate receptors: a novel concept to enhance intracellular drug delivery in cancer therapy |
| Q39728897 | Targeting of the B-lineage leukemia stem cells and their progeny with norcantharidin encapsulated liposomes modified with a novel CD19 monoclonal antibody 2E8 in vitro |
| Q37978315 | Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy |
| Q38703125 | Taxane-Grafted Metal-Oxide Nanoparticles as a New Theranostic Tool against Cancer: The Promising Example of Docetaxel-Functionalized Titanate Nanotubes on Prostate Tumors. |
| Q33792538 | Temperature triggered self-assembly of polypeptides into multivalent spherical micelles |
| Q46622772 | Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system |
| Q26749391 | Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy |
| Q47769245 | The Display of Single-Domain Antibodies on the Surfaces of Connectosomes Enables Gap Junction-Mediated Drug Delivery to Specific Cell Populations |
| Q41696512 | The Effect of Cage Shape on Nanoparticle-Based Drug Carriers: Anticancer Drug Release and Efficacy via Receptor Blockade Using Dextran-Coated Iron Oxide Nanocages. |
| Q35128900 | The dawning era of polymer therapeutics |
| Q27473459 | The hepatitis C virus internal ribosome entry site facilitates efficient protein synthesis in blood vessel endothelium during tumour angiogenesis |
| Q38857110 | The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles |
| Q37815479 | The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting |
| Q34984732 | The role of flexible tethers in multiple ligand-receptor bond formation between curved surfaces |
| Q35816600 | The synergistic effect of folate and RGD dual ligand of nanographene oxide on tumor targeting and photothermal therapy in vivo. |
| Q38328927 | The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy. |
| Q37717652 | The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment |
| Q58738518 | Therapeutic Peptide Amphiphile as a Drug Carrier with ATP-Triggered Release for Synergistic Effect, Improved Therapeutic Index, and Penetration of 3D Cancer Cell Spheroids |
| Q38021996 | Therapeutic siRNA: principles, challenges, and strategies. |
| Q37122166 | Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare |
| Q37211735 | Tissue factor-targeted lidamycin inhibits growth and metastasis of colon carcinoma |
| Q35547765 | Tissue-selective therapy of cancer |
| Q91814809 | Titanate Nanotubes Engineered with Gold Nanoparticles and Docetaxel to Enhance Radiotherapy on Xenografted Prostate Tumors |
| Q53098100 | Toward the Selection of Cell Targeting Aptamers with Extended Biological Functionalities to Facilitate Endosomal Escape of Cargoes. |
| Q33272567 | Towards a ligand targeted enzyme prodrug therapy: single round panning of a beta-lactamase scaffold library on human cancer cells |
| Q28291499 | Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer |
| Q37314094 | Towards new functional nanostructures for medical imaging |
| Q23914977 | Toxicology of nanomaterials used in nanomedicine |
| Q46624404 | Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil |
| Q47108689 | Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery |
| Q38981743 | Trends on polymer- and lipid-based nanostructures for parenteral drug delivery to tumors |
| Q38043525 | Tumor endothelial markers as a target in cancer |
| Q99579061 | Tumor microenvironment responsive drug delivery systems |
| Q33235069 | Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers |
| Q38956549 | Tumor-activated prodrug (TAP)-conjugated nanoparticles with cleavable domains for safe doxorubicin delivery. |
| Q40176991 | Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. |
| Q34974957 | Tumor-targeted RNA-interference: functional non-viral nanovectors |
| Q34770116 | Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models |
| Q36858135 | Tumour-targeted nanomedicines: principles and practice. |
| Q37694413 | Understanding specific and nonspecific toxicities: a requirement for the development of dendrimer-based pharmaceuticals |
| Q42134796 | Unexpected multivalent display of proteins by temperature triggered self-assembly of elastin-like polypeptide block copolymers. |
| Q38957238 | Universal antibody conjugation to nanoparticles using the Fcγ receptor I (FcγRI): quantitative profiling of membrane biomarkers |
| Q42635272 | Uptake of glucose-conjugated MGMT inhibitors in cancer cells: role of flippases and type IV P-type ATPases |
| Q42019801 | Validation of a Janus role of methotrexate-based PEGylated chitosan nanoparticles in vitro |
| Q38794157 | pH sensitive coiled coils: a strategy for enhanced liposomal drug delivery |
| Q34377276 | pH-(low)-insertion-peptide (pHLIP) translocation of membrane impermeable phalloidin toxin inhibits cancer cell proliferation |
| Q39169802 | pH-controlled delivery of nanoparticles into tumor cells |
| Q28730476 | β-Caryophyllene, a Compound Isolated from the Biblical Balm of Gilead (Commiphora gileadensis), Is a Selective Apoptosis Inducer for Tumor Cell Lines |
Search more.